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The downstream targets of hypoxia inducible factor-1 alpha (HIF-1α) play an important role in tumor progression
and angiogenesis. Therefore, inhibition of HIF-mediated transcription has potential in the treatment of cancer. One
attractive strategy for inhibiting HIF activity is the disruption of the HIF-1α/p300 complex, as p300 is a crucial
coactivator of hypoxia-inducible transcription. Several members of the epidithiodiketopiperazine (ETP) family of
natural products have been shown to disrupt the HIF-1α/p300 complex in vitro; namely, gliotoxin, chaetocin, and
chetomin. Here, we further characterized the molecular mechanisms underlying the antiangiogenic and antitumor
effects of these ETPs using a preclinical model of prostate cancer. In the rat aortic ring angiogenesis assay, gliotoxin,
chaetocin, and chetomin significantly inhibited microvessel outgrowth at a GI50 of 151, 8, and 20 nM, respectively.
In vitro co-immunoprecipitation studies in prostate cancer cell extracts demonstrated that these compounds
disrupted the HIF-1α/p300 complex. The downstream effects of inhibiting the HIF-1α/p300 interaction were
evaluated by determining HIF-1α target gene expression at the mRNA and protein levels. Dose-dependent
decreases in levels of secreted VEGF were detected by ELISA in the culture media of treated cells, and the
subsequent downregulation of VEGFA, LDHA, and ENO1 HIF-1α target genes were confirmed by semi-quantitative
real-time PCR. Finally, treatment with ETPs in mice bearing prostate tumor xenografts resulted in significant
inhibition of tumor growth. These results suggest that directly targeting the HIF-1α/p300 complex with ETPs may
be an effective approach for inhibiting angiogenesis and tumor growth.
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Hypoxia, a reduction in tissue oxygen levels below physio-
logical levels, is a nearly universal hallmark of solid tumors,
and commonly develops due to heterogeneous blood flow
from structurally and functionally abnormal blood vessels
within the tumor [1,2]. Intratumoral hypoxia can drive
tumor progression leading to a malignant phenotype that
is associated with increased risk of invasion, metastasis,* Correspondence: figgw@helix.nih.gov
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reproduction in any medium, provided the ortreatment failure, and patient mortality. Adaptation to hyp-
oxia is critical for tumor survival and growth and is medi-
ated through activation of heterodimeric hypoxia inducible
factor 1 (HIF-1), which facilitates transcriptional responses
to changes in oxygen levels [3-7].
HIF-1 is a heterodimeric transcription factor composed
of an O2-regulated HIF-1α subunit and a constitutively
expressed HIF-1β subunit. Under oxygenated condi-
tions, HIF-1α is rapidly degraded via the von Hippel-
Lindau tumor suppressor gene product (pVHL)-mediated
ubiquitin-proteasome pathway. However, in hypoxic con-
ditions, HIF-1α is stabilized and translocates into the nu-
cleus where it binds as a heterodimer with HIF-1β to its
cognate DNA sequence, the hypoxia response elementtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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family of coactivators to initiate the transcription of a di-
verse group of genes involved in the adaptive response to
hypoxia [3,5,7,8].
HIF-1 expression is elevated in many human cancers,
and its levels in cells correlate with tumorigenicity and
angiogenesis, the formation of new blood vessels via the
sprouting and remodeling of preexisting vessels [3-5,9,10].
The newly generated blood vessels are required to supply
adequate oxygen and nutrition to the growing tumor
mass, which further accelerates tumor growth and facili-
tates metastasis. Thus, tumor angiogenesis plays a key role
in cancer cell survival, tumor growth and metastasis
[1,11-13]. In particular, HIF plays a central role in the
activation of multiple genes that encode angiogenic
growth factors, including VEGF, the most potent stimula-
tor of angiogenesis, stromal-derived factor 1 (SDF1), pla-
cental growth factor (PGF), and angiopoietin (ANGPT) 1
and 2 [14,15]. Therefore, inhibition of HIF-1 is an attract-
ive therapeutic strategy for targeting hypoxia and tumor
angiogenesis.
Many HIF-1 inhibitors have been generated in the last
several years, most of which function by altering signal
transduction pathways that are indirectly associated with
HIF or that are part of more complex pathways relevant
to human cancer, clearly limiting their specificity of ac-
tion and increasing their likelihood of toxicity [10,16,17].
As a result, most of these inhibitors have failed in clin-
ical trials. Thus, there is a clear need for direct HIF in-
hibitors, yet no such agent has been clinically developed
to date [10,16]. One promising approach for directly
inhibiting HIF is by disrupting the complex that HIF-1α
forms with p300, an essential transcriptional coactivator
[10,18]. Previous research from our laboratory showed
that several members of the epidithiodiketopiperazine
(ETP) family of fungal secondary metabolites; namely,
gliotoxin, chaetocin, and chetomin are able to block the
interaction between HIF-1α and p300 in vitro by a zinc
ejection mechanism [19,20].
Angiogenesis plays a critical role in prostate cancer de-
velopment and progression, and inhibition of angiogen-
esis in preclinical models has been shown to be an
effective target in metastatic prostate cancer. Thus, in
this study, we used prostate cancer cells as a preclinical
model to further characterize the molecular mechanisms
of these compounds in respect to their antiangiogenic
effects. Data from rat aortic ring assays demonstrated
the antiangiogenic properties of these ETPs, and co-
immunoprecipitation experiments showed that these
effects are due, at least in part, to disruption of the HIF-
1α/p300 complex, which led to a subsequent decrease in
HIF activity. We also demonstrated that these ETPs have
antitumor efficacy in vivo. Taken together, these data in-
dicate that directly inhibiting HIF-1 by targeting theHIF-1α/p300 interaction with these ETPs may prove




PC3 human prostate cancer cells (ATCC; Manassas, VA)
were grown in Ham’s F-12K medium (Gibco; Carlsbad,
CA), and HCT116 human colon cancer cells (ATCC)
were grown in McCoy’s 5a medium (Gibco). Both cell
lines were supplemented with 10% fetal bovine serum
(Atlanta Biologicals; Lawrenceville, GA), 50 U/ml peni-
cillin, and 50 mg/ml streptomycin (Gibco). Cells were
grown in a 37°C incubator with 5% CO2. For hypoxic
conditions, 200 μM of cobalt chloride (CoCl2) was added
to the media, or cells were placed in a modular incuba-
tor chamber flushed with 1% O2, 5% CO2, 94% N2.
Antibodies and reagents
Monoclonal HIF-1α antibody was purchased from BD
Biosciences Pharmingen (San Diego, CA). Monoclonal
p300 antibodies were purchased from Thermo Scientific
(Rockford, IL) and Calbiochem (Billerica, MA). Alexa
Fluor 680 goat anti-mouse IgG for fluorescence detection
using the Odyssey Imaging System was from Molecular
Probes (Eugene, OR). The FITC rabbit anti-mouse sec-
ondary antibody was used for immunofluorescence stain-
ing, and was purchased from Abcam (Cambridge, MA).
Protein A/G Agarose was purchased from Thermo Scientific,
and CoCl2 was purchased from Sigma (St. Louis, MO).
Gliotoxin, chaetocin, and chetomin were purchased from
Sigma, and sorafenib was purchased from Toronto Re-
search Chemicals (Ontario, Canada). Each of the ETPs
and sorafenib were stored frozen in DMSO. Odyssey
blocking buffer was from LICOR (Lincoln, NE).
Rat aortic ring assay
The rat ring assay was performed similarly to that previ-
ously described [21]. Twelve-well tissue culture plates
were covered with 250 μl Matrigel (BD Biosciences) and
allowed to gel for 30 to 45 min at 37°C, 5% CO2. Thoracic
aortas were excised from 6- to 8-week-old male Sprague–
Dawley rats, and the fibroadipose tissue was removed.
The aortas were cut into 1 mm-long cross-sections and
placed on the Matrigel-coated wells. They were then cov-
ered with an additional 250 μl Matrigel and allowed to gel
for 30 to 45 min at 37°C. The rings were cultured for 24 h
in 1 ml EGM-2 (Atlanta Biologicals). After 24 h, the
medium was removed and replaced with 1 ml EBM-2
(Atlanta Biologicals), supplemented with fetal bovine
serum (2%), ascorbic acid, hydrocortisone, heparin, and
amphotericin, at concentrations consistent with EGM-2
media. Each ETP (gliotoxin, chaetocin, chetomin) was dis-
solved in DMSO and added to the EBM media (final
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well. The rings were incubated in treatment media for
5 days, after which they were imaged on an inverted phase
contrast microscope. All images were acquired with Spot
version 4.5 imaging software. Vascular outgrowth was
quantified using Adobe Photoshop CS3 version 10; the
inner portion of the rings was excluded from analysis.
Immunofluorescence
Rat ring assays were performed as described in the previous
section; however, 6-well tissue culture plates were used and
no drug was added. The rings were incubated for 7 days in
EGM-2 media, after which the media was removed and
2 ml of Cell Recovery Solution was added to the wells (BD
Biosciences) to depolymerize the Matrigel and release the
endothelial cells. After a 2-h incubation, the recovery solu-
tion was removed, the cells were washed once in PBS con-
taining 0.1% Tween (PBS-Tween), and were then fixed in
4% paraformaldehyde for 30 min at 37°C. Subsequently, the
cells were washed again with PBS-Tween and perme-
abilized with 0.5% Triton X-100 (Sigma) for 4 min. After
another PBS-Tween wash, the cells were blocked for 1 h in
PBS containing 2% BSA (Sigma), and then incubated for
1 h in a 1:50 dilution of HIF-1α antibody. After three
washes with PBS-Tween, the rings were incubated for 1 h
in the dark with a 1:500 dilution of FITC-labeled anti-
mouse antibody. The cells were washed three times with
PBS-Tween and mounted onto slides with VECTASHIELD
Mounting Medium with DAPI (Vector Laboratories;
Burlingame, CA). Images were taken on an Olympus BX51
microscope with UplanF1 40x lens. InSight Firewire camera
and Spot version 4.5 imaging software were used to capture
the images. Adobe Photoshop CS3 version 10 was used for
after-capture edits where all photos were processed the
same and merged equally.
HIF-1α/p300 co-immunoprecipitation
PC3 cells were treated with media containing 200 μM
CoCl2 and either DMSO or the indicated concentrations
of ETPs. The media covering the cells was removed after
18 h, and the cells were washed once with PBS contain-
ing CoCl2. Cells were then scraped from the plates in
200 μl of ice-cold lysis buffer containing 25 mM Tris,
pH 8.0, 150 mM NaCl, 2 mM EDTA, 1% Triton, and
protease and phosphatase inhibitors (Nacalai; San Diego,
CA). The lysed cells were pipetted into a 1.5-ml
Eppendorf tube, incubated on ice for 30 min, and micro-
centrifuged at 14,000 × g for 30 min at 4°C. Clarified ly-
sates were incubated overnight at 4°C with 0.3 μg of
p300 monoclonal antibody (Calbiochem), and then incu-
bated for 1 h with Protein A/G Agarose. Beads were ex-
tensively washed in lysis buffer, and bound proteins were
eluted in SDS sample buffer and subjected to Western
blot analysis.Western blot analysis
SDS-solubilized protein samples were resolved using
the Novex NuPage SDS-PAGE gel system (Invitrogen;
3-10% Tris Acetate gels for p300 detection, 4-12%
Bis-Tris gels for HIF-1α detection), and electrophoret-
ically transferred to 0.45 μm nylon-supported nitrocel-
lulose membranes (Biorad; Hercules, CA). Membranes
were blocked for 1 h in Odyssey blocking buffer, and
then incubated overnight at 4°C in a 1:1000 dilution of
HIF-1α monoclonal antibody (BD Biosciences) and a
1:500 dilution of p300 monoclonal antibody (Thermo
Scientific). After three washes in lysis buffer for 5 min
each, the membranes were incubated for 1 h at room
temperature in a 1:10,000 dilution of fluorophore-
conjugated goat anti-mouse IgG, and washed another
three times for 10 min each. Bound antibodies were
visualized via the Odyssey Infrared Imaging System
and Odyssey software.Cell viability assays
HCT116 and PC3 cells were seeded overnight into
96-well plates in 100 μl of medium at a concentration of
5 × 104 cells well−1. After overnight incubation at 37°C,
medium was removed and replaced with 200 μl of
medium containing increasing concentrations of ETPs
or vehicle control (DMSO). Plates were placed in either
a normoxic incubator or a hypoxic chamber (Billups-
Rothenberg; Del Mar, CA) for 18 h. Cell viability was
measured by adding 20 μl CellTiter-Blue cell viability
reagent (Promega; Madison, WI) to each well, after
which the cells were returned to the 37°C incubator
until sufficient color change. Fluorescence intensity was
read at 570 nm using a SpectraMax M2 fluorescence
plate reader (Molecular Devices; Sunnyvale, CA).VEGF ELISA
HCT116 and PC3 cells were seeded into 96-well plates
at a concentration of 50,000 cells/ml and 190,000 cells/ml,
respectively. After overnight incubation at 37°C, the
media was removed and replaced with 210 μl serum-
free media containing either drug or vehicle control
(DMSO), in the absence or presence of 200 μM cobalt
chloride. The plates were incubated for 18 h at 37°C.
The supernatant was then collected on ice, after which
the number of viable cells in each well was determined
using the CCK8 assay (Dojindo Molecular Technologies;
Rockville, MD). After cell viability assessment, the concen-
tration of secreted VEGF in the tissue culture supernatant
was determined using the Quantikine human VEGF
ELISA Kit (R & D Biosystems; Minneapolis, MN) accord-
ing to the manufacturer’s instructions. Relative VEGF con-
centrations in the supernatant were normalized to the cell
number in each well.
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HCT116 and PC3 cells were treated for 18 h with ETPs
under hypoxic conditions (hypoxic chamber or treatment
with 200 μM CoCl2). Total RNA extraction was per-
formed using the RNAeasy mini kit (Qiagen; Valencia,
CA) according to the manufacturer’s protocol. RNA con-
centration was determined using a NanoDrop® spectro-
photometer (Molecular Devices). Purified RNA (1.5 μg)
from HCT116 cells was reverse transcribed per 25-μl
cDNA synthesis reaction using the RT2 First Strand kit
(SABiosciences; Valencia, CA) according to the manufac-
turer’s instructions. Purified RNA (0.24-0.32 μg) from PC3
cells was reverse transcribed per 20 μl cDNA synthesis re-
action using The Superscript III First-Strand Synthesis
System for RT-PCR (Invitrogen) according to the manu-
facturer’s protocol.
For qPCR reactions with RNA extracted from HCT116
cells, cDNA reaction products (25 μl) were diluted 1:4 in
water. For each sample, 1 μl each of cDNA, forward and
reverse primers (VEGFA, ENO1, LDHA, ACTB), were
mixed with 2x RT2 SYBR Green/ROX qPCR Master Mix
(SABiosciences) in a total volume of 25 μl. qPCR was per-
formed using a Stratagene Mx3005P™ Real-Time PCR
System with MxPro analysis software (Stratagene; Santa
Clara, CA). For qPCR reactions with RNA extracted from
PC3 cells, cDNA reaction products (20 μl) were diluted
1:3 in water. For each sample, 2 μl of cDNA was mixed
with 18 μl master mix containing 1 μl of forward and re-
verse primers, 7 μl water, and 10 μl Taqman Gene Expres-
sion Master Mix (Applied Biosystems) for a total volume
of 20 μl. qPCR was performed using an Applied Biosys-
tems StepOnePlus Real-Time PCR system with StepOne
Software. All qPCR reactions were run in triplicate.
β-Actin (ACTB) was used as a reference housekeeping
gene. Fold-change in RNA levels was calculated using the
ΔΔCt method (SABiosciences 2009 RT2 Profiler PCR
Array System User Manual; Frederick, MD).
Xenografts
Male, Fox Chase SCID Beige Mice were purchased at
5 weeks of age from the National Cancer Institute Animal
Production Area (Frederick, MD). Animals were housed in
polycarbonate cages, and kept on a 12-h light/dark cycle
with food and water given ad libitum. The National Cancer
Institute is accredited by AAALAC International and fol-
lows the Public Health Service Policy for the Care and Use
of Laboratory Animals. Animal care was provided in ac-
cordance with the procedures outlined in the “Guide for
Care and Use of Laboratory Animals” (National Research
Council; 1996; National Academy Press; Washington, DC).
The study protocol was approved by the NCI Animal Care
and Use Committee (Bethesda, MD).
Xenografts were generated by subcutaneously injesct-
ing mice with 3 million PC3 or DU-145 cells suspendedin 100 μl of sterile PBS. Tumor volume (V) was calcu-
lated according to the following formula: V = length ×
width × heigth × 0.52. When tumor volume reached
100 mm3, mice were divided randomly into treatment
and control groups of 7 rats each. ETPs and vehicle
(12.5% DMSO, 37.5% PEG 400, 50% sterile saline) were
administered to the animals by daily intraperitoneal in-
jection at the previously determined MTD doses of
0.50 mg/kg, 0.25 mg/kg, and 0.50 mg/kg for gliotoxin,
chaetocin, and chetomin, respectively, at a dosing vol-
ume of 5 ml/kg. Tumors were measured 3 times a week.
After 2 weeks, tumors were excised and frozen for sub-
sequent immunohistochemistry analysis.
Immunohistochemistry
Frozen samples of tumor xenografts were submitted to
the Pathology/Histotechnology Laboratory (PHL) at
NCI-Frederick. Samples were thawed in 10% buffered
neutral formalin, paraffin-embedded, and cut into 5-mm
sections. Staining was performed using the Bond Max
Autostainer from Leica Biosystems (Buffalo Grove, IL).
EDTA was used for antigen retrieval and 10% normal
rabbit serum (Vector Laboratories) was used as blocking
buffer. Sections were incubated with a 1:100 dilution of
VEGF or CD31 antibodies (R & D Systems) for 30 min,
followed by incubation with a 1:500 dilution of biotinyl-
ated secondary antibody (Vector Laboratories) for 30 min.
Immune reactivity was visualized with the Intense R
Detection Kit (Leica Biosystems). Sections were counter-
stained with hematoxylin and eosin (H & E). All slides
were imaged on an Aperio bright field ScanScope.
Statistical analysis
Analysis of variance (ANOVA) was performed on either
raw or transformed data. Various fixed effects models,
mixed models, or repeated measures ANOVA were used
as appropriate. Hochberg’s method was used for adjust-
ing p-values for multiple comparisons. For the xenograft
model, treatment groups were compared using Mann–
Whitney U test. P values less than 0.05 were considered
statistically significant, and all reported p-values are
two-tailed.
Results
ETPs decrease microvessel outgrowth from rat aortic rings
To determine if gliotoxin, chaetocin, and chetomin have
antiangiogenic properties, a series of rat aortic ring as-
says were performed with increasing concentrations of
each ETP. Specifically, ETPs were added to the culture,
and their effect on vessel outgrowth was determined
using image analysis software to measure the length and
abundance of the sprouting microvessels. DMSO was
used as a negative control and sorafenib, a known anti-
angiogenic agent used to treat hepatocellular carcinoma
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As seen in Figure 1A, a dose-dependent decrease in
microvessel outgrowth occurred with increasing concen-
trations of each ETP. Quantification of vessel outgrowth,
where mean percent inhibition of vessel growth was
compared to vehicle, confirmed the dose-dependent
effect of the ETPs (Figure 1B). At a concentration of
25 nM, gliotoxin exhibited little to no effect on out-
growth, whereas inhibition was statistically evident at
concentrations of 250 nM and above; 500 nM of glio-
toxin led to greater than 90% inhibition (p < 0.0001). At
concentrations of 1 and 5 nM, chaetocin and chetomin
had little effects on outgrowth, but 25 nM and above led
to inhibition of angiogenesis; 100 nM of either ETP
inhibited approximately 90% of microvessel outgrowth
(p < 0.0001). The GI50 of gliotoxin, chaetocin, and cheto-
min was 151, 8, and 20 nM, respectively.
A previous in vitro study from our laboratory used a
fluorescent binding assay to show that ETPs are capable
of disrupting the interaction between the C-TAD do-
main of HIF-1α and the CH1 domain of p300, and elec-
trospray ionization mass spectrometry (ESI-MS) analyses
determined that this occurs via a zinc ejection mechan-
ism [19,22,23]. Since the interaction between HIF-1α
and p300 is critical for transactivation, blocking this
complex reduces HIF-1α-induced transcription of angio-
genic genes [23-25]. Thus, it seemed likely that the anti-
angiogenic effects of the ETPs observed in the rat aortic
ring assays were mediated through disruption of the
HIF-1α/p300 complex. To test this hypothesis, we first
immunostained the aortic rings for HIF-1α to confirm
its presence in the endothelial cells of the microvessel
outgrowth (Figure 1C).
ETPs disrupt the interaction of HIF-1α and p300 in cells
Next, we performed co-immunoprecipitation experiments
to determine if the ETPs could disrupt the interaction of
endogenous HIF-1α and p300. Briefly, endogenous p300
was immunoprecipitated from PC3 human prostate can-
cer cells under hypoxic conditions in the absence and
presence of ETPs, and co-immunoprecipitated HIF-1α
was detected by Western blotting. The low and high con-
centrations of ETPs used in this experiment represented
those concentrations that either had little effect on angio-
genesis or that inhibited approximately 90% of microvessel
outgrowth in the rat ring assay, respectively. As expected,
the expression levels of p300 in the cell lysates remained
the same under both normoxia and hypoxia (200 μM
CoCl2; a hypoxia mimetic), and no HIF-1α expression
could be seen under normoxic conditions (Figure 2A, B;
left panel). Western blot analysis of the immune com-
plexes showed no effect in the presence of 25 nM glio-
toxin; however, in the presence of 500 nM gliotoxin, less
HIF-1α co-immunoprecipitated with p300 (Figure 2A;right panel). Similarly, treatment of cells with only 5 nM
chetomin did not cause disruption of the complex, but
100 nM chetomin was able to disrupt the HIF-1α/p300
complex (Figure 2B; right panel). Neither gliotoxin nor
chetomin affected the expression levels of HIF-1α or p300
under hypoxic conditions. Thus, the observed decrease in
the amount of HIF-1α in the p300 immunoprecipitates
upon treatment with gliotoxin and chetomin demon-
strates their ability to disrupt the interaction between
HIF-1α and p300 in cells. In accordance with a previous
study [26], chaetocin treatment inhibited HIF-1α expres-
sion in a dose-dependent manner (data not shown); thus,
co-immunoprecipitations could not be performed from
chaetocin-treated cells.
ETPs decrease VEGF secretion in a dose-dependent manner
To determine whether blocking the HIF-1α/p300 com-
plex in cells with ETPs affected angiogenic signaling,
VEGF secretion was examined in the presence of ETPs
since VEGF is a prominent target of HIF-1α and a po-
tent stimulator of angiogenesis. To this end, PC3 cells
were treated with different concentrations of each ETP
under hypoxic conditions. After 18 hours of treatment,
cell culture media was collected, and a VEGF ELISA was
performed to measure the effects of ETPs on VEGF
levels in the media. As shown in Figure 3A, treatment
with gliotoxin, chaetocin, and chetomin led to a dose-
dependent decrease in hypoxia-induced VEGF expres-
sion. This trend was also seen in HCT116 colorectal
carcinoma cells (Additional file 1: Figure S1A), indicat-
ing that the observed effects with ETPs were not limited
to PC3 cells. Interestingly, gliotoxin did not have an ef-
fect on VEGF expression in this cell line (at the concen-
trations shown), signifying that this compound may have
cell-specific effects.
To ensure that the observed decrease in secreted VEGF
levels was not due to a nonspecific reduction in cell viabil-
ity, PC3 cells were treated with increasing concentrations
of gliotoxin, chaetocin, and chetomin under hypoxic condi-
tions, followed by measurement of cell viability. Significant
toxicity was not observed, as only concentrations close to
10 μM decreased cell viability to approximately 50% in
both cell lines (Figure 3B), whereas nanomolar concen-
trations of ETPs, which did not impact cell viability,
were able to significantly reduce VEGF levels (Figure 3A).
Similar results were obtained for HCT116 cells up to 1
µM (Additional file 1: Figure S1B). Together with our pre-
vious data, these results demonstrate that the potent effect
of these ETPs in reducing VEGF protein levels was not
caused by general cellular cytotoxicity.
ETPs inhibit HIF-1α transcriptional activity
Since HIF-1α is a transcription factor, it was important
to determine if disrupting the HIF-1α/p300 complex
Figure 1 (See legend on next page.)
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Figure 1 Rat ring assay shows dose-dependent inhibition of microvessel outgrowth by ETPs. A, Cells were treated with DMSO (negative
control), 1 μM sorafenib (positive control), and increasing concentrations of gliotoxin, chaetocin, and chetomin. Three concentrations of each ETP
are shown to illustrate the dose-dependent effect of the drugs on microvessel outgrowth. B, Dose response curves showing a decrease in
outgrowth with increasing ETP concentrations. Gliotoxin, chaetocin, and chetomin had a GI50 of 151, 8, and 20 nM, respectively. Data points are
presented as mean S.E.M (error bars) from independent experiments run in triplicate (n = 6). *, p < 0.05, **, p < 0.001, ***, p < 0.0001. C, Rat aortic
rings at day 5 were stained with a HIF-1α monoclonal primary antibody and a FITC-conjugated secondary antibody to label endothelial cells. The
merged image shows DAPI-stained nuclei in blue and HIF-1α expression in green (indicated by arrows). Three representative images are shown.
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there are several pathways and processes that regulate
the production of VEGF protein [27,28], we could not
definitively ascertain that the observed decrease in se-
creted VEGF was due to a decrease in HIF-1α activity.
Therefore, as a way to measure HIF-1α transcriptional
activity, we performed qPCR in the absence and pres-
ence of ETPs and monitored levels of VEGF mRNA. As
an additional way of demonstrating the specificity of
HIF-1α transcriptional activation, we also monitored the
levels of two other HIF-1α target genes; namely lactateFigure 2 ETPs disrupt the endogenous HIF-1α/p300 complex in cells.
presence or absence of the indicated concentrations of gliotoxin and chae
the cell lysates using a p300 mouse monoclonal antibody and Protein A/G
immunoblot analysis of the lysates (left panels) and immune complexes (rig
with 25 nM and 500 nM gliotoxin (GLIO). B, Treatment with 5 nM and 100dehydrogenase A (LDHA) and enolase-1 (ENO1), which
have one hypoxia response element (HRE) and three
HRE sites, respectively that are required for expression
[29]. Briefly, PC3 cells were incubated under normoxic
or hypoxic conditions in the absence or presence of
the indicated concentrations of gliotoxin, chaetocin,
and chetomin. After 18 hours, total cellular RNA was
extracted from the cells, followed by qPCR; β-actin was
used as a reference housekeeping gene. As shown in
Figure 4, levels of VEGF, LDHA, and ENO1 were lower
in normoxia, and increased about 2-fold under hypoxicPC3 cells were cultured under normoxia or hypoxia (CoCl2) in the
tocin. After 18 h, co-immunoprecipitations were performed from
Agarose. Bound proteins were eluted with SDS buffer followed by
ht panels) with antibodies recognizing p300 and HIF-1α. A, Treatment
nM chaetocin (CTM) (n = 3 for all).
Figure 3 ETPs decrease VEGF secretion in a dose-dependent
manner. A, Hypoxia was induced for 18 h in PC3 cells in the
absence or presence of the indicated concentrations (1000 nM is
not shown) of gliotoxin, chaetocin, and chetomin. This was followed
by ELISA quantification of secreted VEGF normalized to DMSO under
hypoxic conditions. A repeated measures ANOVA was performed
on the data; Hochberg’s post-hoc method was used to adjust the
p-values. Data are presented as mean ± S.E.M from independent
experiments run in triplicate (n = 2-7). *, p < 0.05, **, p < 0.001,
***, p < 0.0001. B, PC3 cells were treated with increasing concentrations
of ETPs or with vehicle control (DMSO). Plates were placed in either a
normoxic incubator or hypoxic chamber for 18 h. Cell viability was then
determined using the CellTiter-Blue cell viability reagent. Data points are
presented as mean ± S.E.M from independent experiments run in
triplicate (n= 4).
Figure 4 ETPs decrease expression of HIF-1α-dependent target
genes. PC3 cells were seeded into 6-well plates and incubated for
18 h under normoxic or hypoxic conditions, in the absence or
presence of the indicated concentrations of gliotoxin (top panel),
chaetocin (middle panel), or chetomin (bottom panel). Total RNA was
harvested and tested for VEGF, LDHA, and ENO1 mRNA expression by
qPCR, as described in the Materials and methods. Results are
expressed as fold increase relative to mRNA levels under hypoxic
conditions in the absence of ETPs. β-actin was tested in parallel as
an internal control for input RNA. Results are the mean ± S.E.M of
independent experiments run in triplicate (n = 2-5). A repeated
measures ANOVA was performed on the data with Hochberg’s
post-hoc method. *, p < 0.05, **, p < 0.001, ***, p < 0.0001.
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tional activity increases under hypoxic conditions due to
a lack of prolyl hydroxylases, which cause HIF-1α deg-
radation under normoxia. There was a significant de-
crease in ENO1 levels at each gliotoxin concentration
tested (p < 0.0001), and in LDHA concentrations of 100
nM and above (p < 0.0001). VEGF expression decreased
with 250 nM gliotoxin but did not reach statistical sig-
nificance (Figure 4; top panel). This observed decrease
in HIF-1α gene expression upon ETP treatment was also
confirmed in HCT116 cells (Additional file 2: Figure S2;
top panel), although similar to what we observed in the
VEGF ELISA, gliotoxin treatment of HCT116 cells did
not affect VEGF gene expression, nor were decreases ob-
served in levels of LDHA or ENO1, indicating that
gliotoxin does not target HIF-1α in this cell line. When
PC3 cells were treated with chaetocin (Figure 4; middle
panel) and chetomin (Figure 4; bottom panel) under
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http://www.molecular-cancer.com/content/13/1/91hypoxic conditions, there was a significant decrease in
VEGF, LDHA, and ENO1 gene expression to approxi-
mately normoxic levels at each of the indicated concen-
trations (p<0.05). Similar effects of chaetocin (VEGF
and LDHA only) and chetomin (VEGF only) were seen
in HCT116 cells as well (Additional file 2: Figure S2;
middle and bottom panels). Together, these data demon-
strate that disrupting the HIF-1α/p300 complex by ETPs
has functional consequences, as revealed by the inhibi-
tory effect of ETPs on HIF-1α transactivation in both
cell lines.
ETPs inhibit xenograft tumor growth
In order to evaluate whether disruption of the HIF-1α/
p300 complex by ETPs affected the growth of human
tumor xenografts, PC3 cells were implanted subcutane-
ously into severe combined immunodeficiency (SCID)
mice. Once tumors had grown to approximately 100 mm3,
vehicle or ETPs were administered for 15 days by daily
intraperitoneal injection. As seen in Figure 5A (top panel),
compared to mice treated with vehicle control, 0.50 mg/kg
gliotoxin (p = 0.0037), 0.25 mg/kg chaetocin (p = 0.0020),
and 0.50 mg/kg chetomin (p = 0.0037) had significantFigure 5 ETPs attenuate tumor growth in vivo. A, Mice with approxima
injection for 15 days with gliotoxin (0.50 mg/kg), chaetocin (0.25 mg/kg), c
approximately 100 mm3 DU-145 xenografts were treated by daily intraperit
control (bottom panel). Results are the mean of 6–7 independent tumors ±
varying degrees of necrosis (top panel). Statistical significance was determin
Low-power views (2x and 10x) of H & E-stained tumor sections from PC3 x
vehicle- and gliotoxin-treated tumors, which had the highest incidence ofantitumor activity. Since all of the ETPs had similar antitu-
mor activity, we chose just one (gliotoxin) to move for-
ward with in another xenograft study using DU-145
human prostate cancer cells. Similar to the PC3 xenograft
model, gliotoxin had significant antitumor activity in
DU-145 xenografts (Figure 5A; bottom panel). Daily ad-
ministration of ETPs did not cause major weight loss (data
not shown). Finally, histological examination of tumor
sections revealed significant necrosis in gliotoxin-treated
tumors compared to mice that received chaetocin, cheto-
min, or vehicle (Figure 5B). Immunostaining for VEGF
and CD31 did not reveal appreciable differences between
treatment groups (data not shown), although the variabil-
ity in staining made the data difficult to interpret. Similar
immunostaining issues were seen in the study by Kung
et al., who noted that immunostaining for VEGF revealed
vast regional variability in chetomin-treated tumors [23].
Discussion
Here, we show that ETPs abrogate hypoxia-induced tran-
scription by disrupting the HIF-1α and p300 interaction,
with consequent antiangiogenic and antitumor effects.
Angiogenesis, the recruitment of new blood vessels fromtely 100 mm3 PC3 xenografts were treated by daily intraperitoneal
hetomin (0.50 mg/kg), or vehicle control (top panel). Mice with
oneal injection for 15 days with gliotoxin (0.50 mg/kg) or vehicle
S.E.M. B, Graphical representation of the percent of animals with
ed using the Mann–Whitney U test. *, p < 0.05, **, p < 0.005.
enografts (bottom panel). The arrows indicate areas of necrosis in
necrosis.
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metastasis of solid tumors, as tumors will not grow be-
yond 1 to 2 mm in diameter without an independent
blood supply [30]. Thus, inhibition of angiogenesis has
emerged as a promising strategy for cancer treatment.
Since the progression of cancer leads to hypoxic condi-
tions that stimulate angiogenesis, an important objective
of anti-cancer therapy is the development of new drugs
that suppress the hypoxic response in solid tumors. HIF-1
is the most important mediator of a cell’s response to hyp-
oxia, as it regulates genes that enable the cell to survive in
the hypoxic environment, including those involved in cell
proliferation, metastasis, and glycolysis [6].
One promising approach for directly inhibiting HIF ac-
tivity is by using small molecules to target the critical
interaction between HIF-1α and its coactivator, p300.
Previous research from our laboratory and others
showed that select members of the ETP family of fungal
metabolites were able to disrupt the interaction between
HIF-1α and p300 using an in vitro cell-free system
[19,20,23]; namely, gliotoxin, chaetocin, and chetomin,
all of which have a wide range of biological activities, in-
cluding antimicrobial, anti-inflammatory, and anticancer
effects [23,31,32]. In the present study, we further char-
acterized the molecular mechanisms of the antiangio-
genic and antitumor effects of ETPs using an ex vivo
angiogenesis assay, in vitro cellular assays, and an in vivo
animal model of prostate cancer. We began our studies
with the rat aortic ring assay, which is a useful assay for
testing angiogenic factors or inhibitors in a controlled
environment. This model integrates the advantages of
both in vivo and in vitro systems, and is unique in that
it recapitulates all of the key steps in the angiogenic
process; namely, matrix degradation, migration, prolifer-
ation, and reorganization [33]. Our data showed that
each ETP caused a dose-dependent decrease in micro-
vessel outgrowth, indicating that they possessed antian-
giogenic activities in vitro. This is in accordance with
data from Lee et al., which showed that gliotoxin signifi-
cantly inhibited angiogenesis, as assessed by a tube for-
mation assay in human umbilical vein endothelial cells
(HUVECs) [34].
To determine if the mechanism underlying their activity
was via disruption of the HIF-1α/p300 complex, co-
immunoprecipitation experiments of the endogenous
complex were carried out in PC3 cells. Treatment of pros-
tate cancer cells with gliotoxin and chetomin blocked
the ability of HIF-1α to interact with p300, which is in
accordance with previous cellular studies that showed
disruption of the HIF-1α/p300 complex in HepG2 liver
hepatocellular cells with chetomin [23], as well as in vitro
studies that used recombinant proteins to show that glio-
toxin [19,22] and chetomin [19,22,23] disrupted the bind-
ing of HIF-1α and p300. While in vitro studies have alsoshown that chaetocin is able to disrupt HIF-1α and p300
binding [19,35], we could not demonstrate this in our co-
immunoprecipitation studies because interestingly, treat-
ment with chaetocin decreased HIF-1α protein expression.
A similar effect was seen in a study by Lee et al. [26],
which demonstrated that the hypoxic induction of HIF-1α
was attenuated by chaetocin in human hepatoma cell
lines. The authors later concluded that the antiangiogenic
and anticancer effects of chaetocin against hepatoma were
via deregulation of HIF-1α premessenger RNA splicing.
Taken together, these findings suggest that ETPs exhibit
more than one mechanism of action, and these effects
may be cell-type specific.
Our ELISA and qPCR experiments demonstrated the
ability of the ETPs to prevent VEGF production in PC3
cells under hypoxic conditions. Interestingly, in HCT116
cells, gliotoxin did not have an effect on VEGF expres-
sion or that of the other HIF-1α target genes analyzed,
indicating that gliotoxin does not target HIF-1α in this
cell line. Previous work has suggested that the antitumor
activity of gliotoxin against breast cancer in vivo may be
through its ability to inhibit farnesyltransferases [32].
Since inhibition of this enzyme was recently shown to
reduce angiogenesis by interrupting endothelial cell mi-
gration [35], farnesyltransferase could be a target of glio-
toxin in HCT116 cells.
Finally, we demonstrated that gliotoxin, chaetocin, and
chetomin were able to significantly decrease tumor growth
in a xenograft model of prostate cancer. It is worth noting
that we treated the mice with 0.50 mg/kg chetomin, with
no significant weight loss observed, in comparison to the
1–2 mg/kg chetomin that induced toxicity in a previous
study [23]. We also measured the extent of necrosis in
tumor sections stained with H & E, and found a statisti-
cally significant increase in necrosis in tumors treated with
gliotoxin compared to vehicle, chaetocin- and chetomin-
treated tumors. This is consistent with the fact that under
hypoxic conditions, oxidative phosphorylation is impaired
leading to the induction of glycolytic enzymes, which
maintain the basal level of adenosine 5’-triphosphate re-
quired for cell survival [36]. Therefore, inhibition of glyco-
lytic genes, such as LDHA and ENO1, by ETPs most likely
played a role in inhibiting cell survival under hypoxia
and promoting cell death in hypoxic areas. Thus, although
the ETPs exhibited antiangiogenic effects in vitro, their
mechanism of action in vivo, at least at the dose tested,
appears to be via direct cytotoxic effects on tumor cells.
This may explain why VEGF and CD31 did not reveal ap-
preciable differences between vehicle and ETP treatment
groups, although as noted earlier, definitive conclusions
could not be made since the immunostaining data were
difficult to interpret.
In conclusion, although a number of anticancer drugs
have been shown to inhibit HIF, none of these drugs have
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most HIF-1 inhibitors that have been put forth have failed
to demonstrate therapeutic efficacy in clinical trials for
cancer patients, and these failures have been due, at least
in part, to their lack of specificity. Thus, there has been a
clear need for novel, potent, inhibitors that target clearly
defined points in the HIF pathway. Although future stud-
ies are needed to characterize the specificity of ETPs, par-
ticularly with respect to other zinc-binding proteins, the
results presented suggest that directly targeting the HIF-
1α/p300 complex with ETPs may be an effective approach
for inhibiting angiogenesis and tumor growth. While the
usefulness of ETPs such as chetomin or gliotoxin is lim-
ited by their toxicity, there specificity in targeting HIF-1
makes them attractive molecules for the design of future
chemotherapeutic agents.
Additional files
Additional file 1: Figure S1. ETPs decrease VEGF secretion in HCT116
cells. A, Hypoxia was induced for 18 h in HCT116 cells in the absence or
presence of the indicated concentrations of ETPs, followed by ELISA
quantification of secreted VEGF normalized to DMSO under hypoxic
conditions (n = 1-6). A repeated measures ANOVA was performed on the
data; Hochberg’s method was used to adjust the p-values. *, p < 0.05,
**, p < 0.001, ***, p < 0.0001. B, Cell viability was determined in HCT116
cells using the CellTiter-Blue cell viability reagent. Data points are
presented as mean ± S.E.M from independent experiments (n=3-7).
Additional file 2: Figure S2. ETPs decrease expression of HIF-1α-
dependent target genes in HCT116 cells. Cells were incubated in the
absence or presence of the indicated concentrations of gliotoxin (top
panel), chaetocin (middle panel), and chetomin (bottom panel). Total RNA
was harvested and tested for VEGF, LDHA, and ENO1 mRNA expression by
qPCR. Results are expressed as fold increase relative to mRNA levels
under normoxic conditions in the absence of ETPs. β-actin was tested in
parallel as an internal control for input RNA. Results are the mean ± S.E.M
of independent experiments run (n=2-6). A repeated measures ANOVA
was performed on the data; Hochberg’s method was used to adjust the
p-values *, p < 0.05, **, p < 0.001, ***, p < 0.0001.
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